Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $11.900 million which beat the analyst consensus estimate of $2.800 million by 324.98 percent. This is a 232.59 percent increase over sales of $3.578 million the same period last year.